10-K · May 29, 2026
STERIS plc reported strong financial performance for the year ended March 31, 2026, with revenues increasing 8.7% to $5.93 billion. The company showed improvements in gross margins and operating income while…
Earnings analysis · 10-Q
STE earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
STERIS reported $1.4927 billion of revenue and diluted EPS of $2.59, with EPS above the $2.51 consensus estimate but revenue below the $1.5000 billion estimate. The filing excerpt does not provide sufficient…
Read full summary
STERIS reported $1.4927 billion of revenue and diluted EPS of $2.59, with EPS above the $2.51 consensus estimate but revenue below the $1.5000 billion estimate. The filing excerpt does not provide sufficient income-statement detail to assess gross margin, operating margin, segment trends, balance-sheet changes or free cash flow. Management reported no material change in market-risk exposure since March 31, 2026, while expanding share repurchases through a new $1.000 billion authorization.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $2.59
What stood out
-
EPS Beat Despite Revenue Miss
Reported revenue was $1.4927 billion and diluted EPS was $2.59 for the quarter. EPS exceeded the provided consensus estimate of $2.51, while revenue was below the $1.5000 billion estimate.
-
Expanded Share Repurchase Capacity
The company replaced its $500.0 million outgoing repurchase authorization with a new $1.000 billion program on May 5, 2026. It repurchased 0.5 million shares for $100.0 million during the quarter, leaving $900.0 million available at June 30, 2026.
-
Market Exposures Remain Managed
Management stated that market-risk exposures had not changed materially since March 31, 2026. At June 30, 2026, the company held currency forwards covering 48.0 million euros, 7.0 million Australian dollars, 7.0 million New Zealand dollars and 175.0 million Mexican pesos, plus commodity swaps covering 0.5 million pounds of nickel.
What to watch
-
Unhedged Accounting Volatility
The company does not elect hedge accounting for its foreign-currency earnings forwards and warns of volatility from timing mismatches and reporting classification. At June 30, 2026, its hedging portfolio included contracts to sell 48.0 million euros and buy 175.0 million Mexican pesos.
-
Raw-Material Cost Exposure
Management states that raw-material availability and pricing can affect results and that material costs can rise suddenly, increasing production costs. The company held commodity swaps to buy 0.5 million pounds of nickel at June 30, 2026.
-
Large Capital Allocation Commitment
The company committed $100.0 million to repurchases during the first three months of fiscal 2027, while the new program authorizes up to $1.000 billion and had $900.0 million remaining at June 30, 2026. This represents a significant use of capital that could otherwise support liquidity, investment or debt reduction.
Management's outlook
The 10-Q does not provide new quantitative revenue or EPS guidance; the prior 10-K outlook was fiscal 2027 revenue growth of 7%-8% and EPS of $11.10-$11.30.
Earlier filings 4
10-Q · February 6, 2026
STERIS plc reported strong Q3 FY2026 results with total revenue of $1.5 billion, reflecting a 9.2% increase compared to the prior year, driven by growth across all segments. Diluted EPS met estimates at $2.53, while…
10-Q · November 6, 2025
STERIS plc reported strong financial results for Q2 FY2026, with revenue increasing by 9.9% to $1.46 billion compared to the prior year. EPS also rose significantly from $1.51 to $2.47, reflecting strong operational…
10-Q · August 7, 2025
STERIS plc reported strong Q1 fiscal 2026 earnings with an 8.7% year-over-year revenue increase to $1.39 billion, exceeding analyst expectations. The company's gross margin improved to 45.1%, reflecting effective…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.